Compare Smith & Nephew plc (SNN) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Under Armour Inc Class A — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Smith & Nephew plc is far larger — about 5.4× Under Armour Inc Class A's market cap, and Smith & Nephew plc pays a 2.95% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Under Armour Inc Class A for 99 Days on average.
| SNN | UAA | |
|---|---|---|
Market Cap | $11.10B | $2.07B |
Volume | 1,051,703 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $37.17 | $8.14 |
52-Week Low | $26.42 | $4.17 |
Typical Hold Time | 121 Days | 99 Days |
Enterprise Value | $14.13B | $3.05B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and declining revenue trends, though valuation metrics like P/S (0.42) appear attractive. Recent news highlights brand transformation efforts amid softer demand, with the company maintaining profitability outlook despite revenue cuts.
The outlook remains cautious with significant execution risks as Under Armour navigates weak consumer spending. Analyst consensus shows modest upside to the $5.79 price target, but persistent revenue declines and negative cash flow trends pose substantial headwinds for shareholder value recovery in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
